FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors ...

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors ...

Don’t Say “I Don’t Know” in Your PhD/DrPH/Job Interview…………Here’s What to Say Instead! In a PhD interview, being caught off-guard by a question ...

An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer ...

Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, offering a new treatment option for cardiovascular protection. Sotagliflozin, a re ...

Pulmonary Artery Pressure Monitoring Falls Short, New Diuretic Insights Emerge Oak Ridge, TN, Feb. 19, 2025 (GLOBE NEWSWIRE) ...

the MBA/MPH for public health professionals, and the MBA in combination with our surgical residency, for surgeons-in-training. Contact the School of Management for more information about these ...

You're reaching for your keys in the parking lot after a doctor's visit when it hits you, "What did my physician say I wasn't ...

A multimodal, digital community-based intervention was feasible and decreased illness-related distress in treating patients ...

In this episode, Scott Becker speaks with Sohail Azeem, MBA, MPH, FACHE, Chief Operating Officer of MedSys Health. Sohail discusses the company's mission to improve access, prevent adverse ...